Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 1/2 1

Status

Terminated 1Completed 1Active not recruiting 1

Sponsor Class

INDUSTRY 2OTHER_GOV 1

Study Type

Interventional 3

Sponsor

Cancer Type

Head & Neck 6Gastrointestinal 3Thoracic 1Genitourinary 1Dermatologic 1

Conditions

Stomach Neoplasms 172Esophageal Neoplasms 161Esophageal Squamous Cell Carcinoma 116Cholangiocarcinoma 77Pancreatic Neoplasms 73Biliary Tract Neoplasms 72Adenocarcinoma Of Esophagus 52Gallbladder Neoplasms 39Colorectal Neoplasms 36Neoplasm Metastasis 30Carcinoma, Non-Small-Cell Lung 28Carcinoma, Hepatocellular 28Neoplasms 27Bile Duct Neoplasms 24Ovarian Neoplasms 19Liver Neoplasms 17Parkinson Disease 4, Autosomal Dominant Lewy Body 15Colonic Neoplasms 13Peritoneal Neoplasms 12Gastrointestinal Neoplasms 12Anus Neoplasms 12Squamous Cell Carcinoma of Head and Neck 11Adenocarcinoma 11Rectal Neoplasms 9Melanoma 9Lung Neoplasms 9Carcinoma, Squamous Cell 9Breast Neoplasms 9Sarcoma 8Hepatoblastoma 8

Interventions

pembrolizumab 3Paclitaxel 3Cisplatin 3Fluorouracil 2sintilimab 1poly ICLC 1osimertinib 1fludarabine phosphate 1fludarabine 1enzalutamide 1durvalumab 1cobimetinib 1atezolizumab 1advexin 1Vorinostat 1Taxes 1Radiotherapy 1Pemetrexed 1Nivolumab 1Neoadjuvant Therapy 1Mitomycins 1Mitomycin 1Injections 1High-Intensity Focused Ultrasound Ablation 1Cyclophosphamide 1Capecitabine 1Biological Products 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Neoplasms, Squamous Cell × Cisplatin × Gastrointestinal × Clear all
NCT04198766 2025-12-18

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Inhibrx Biosciences, Inc

Phase 1/2 Active not recruiting
296 enrolled
DermatologicGastrointestinalGenitourinaryHead & NeckThoracic

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Carcinoma, Squamous Cell, Carcinoma, Transitional Cell, Head and Neck Neoplasms, Hypopharyngeal Neoplasms, Lung Neoplasms, Melanoma, Mouth Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial, Oropharyngeal Neoplasms, Stomach Neoplasms, Neoplasms, Squamous Cell

NCT03748134 2023-10-24

Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma ( ORIENT-15 )

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3 Completed
746 enrolled
Gastrointestinal

Esophageal Squamous Cell Carcinoma, Carcinoma, Squamous Cell, Esophageal Diseases, Esophageal Neoplasms, Gastrointestinal Diseases, Neoplasms, Squamous Cell

NCT00559351 2007-11-16

RCT on the Combined Modality Treatment of Squamous Cell Carcinoma of the Esophagus

Ministry of Scientific Research and Information Technology, Poland

Phase 3 Terminated
84 enrolled
Gastrointestinal

Esophageal Neoplasms, Neoplasms, Squamous Cell

Data powered by HemOnc (CC BY 4.0) Colophon ⚡